OBJECTIVE: To evaluate the association of nicotinic acetylcholine receptor (nAChR) single nucleotide polymorphism (SNP) with 7-day point prevalence abstinence (abstinence) in randomized clinical trials of smoking cessation therapies in individuals grouped by pharmacotherapy randomization to inform the development of personalized smoking cessation therapy. MATERIALS AND METHODS: We quantified association of four SNPs at three nAChRs with abstinence in eight randomized clinical trials. Participants were 2633 outpatient treatment-seeking, self-identified European ancestry individuals smoking at least 10 cigarettes/day, recruited through advertisement, prescribed pharmacotherapy, and provided with behavioral therapy. Interventions included nicotine replacement therapy (NRT), bupropion, varenicline, placebo (PLA), or combined NRT and bupropion, and five modes of group and individual behavioral therapy. Outcome measures tested in multivariate logistic regression were end of treatment and 6 month (6MO) abstinence, with demographic, behavioral, and genetic covariates. RESULTS: 'Risk' alleles previously associated with smoking heaviness were significantly (P<0.05) associated with reduced abstinence in the PLA pharmacotherapy group (PG) at 6MO [for rs588765, odds ratio (95% confidence interval) 0.41 (0.17-0.99)], and at end of treatment and at 6MO [for rs1051730, 0.42 (0.19-0.93) and 0.31 (0.12-0.80)], and with increased abstinence in the NRT PG at 6MO [for rs588765, 2.07 (1.11-3.87) and for rs1051730, 2.54 (1.29-4.99)]. We observed significant heterogeneity in rs1051730 effects (F=2.48, P=0.021) between PGs. CONCLUSION:chr15q25.1nAChRSNP risk alleles for smoking heaviness significantly increase relapse with PLA treatment and significantly increase abstinence with NRT. These SNP-PG associations require replication in independent samples for validation, and testing in larger sample sizes to evaluate whether similar effects occur in other PGs.
RCT Entities:
OBJECTIVE: To evaluate the association of nicotinic acetylcholine receptor (nAChR) single nucleotide polymorphism (SNP) with 7-day point prevalence abstinence (abstinence) in randomized clinical trials of smoking cessation therapies in individuals grouped by pharmacotherapy randomization to inform the development of personalized smoking cessation therapy. MATERIALS AND METHODS: We quantified association of four SNPs at three nAChRs with abstinence in eight randomized clinical trials. Participants were 2633 outpatient treatment-seeking, self-identified European ancestry individuals smoking at least 10 cigarettes/day, recruited through advertisement, prescribed pharmacotherapy, and provided with behavioral therapy. Interventions included nicotine replacement therapy (NRT), bupropion, varenicline, placebo (PLA), or combined NRT and bupropion, and five modes of group and individual behavioral therapy. Outcome measures tested in multivariate logistic regression were end of treatment and 6 month (6MO) abstinence, with demographic, behavioral, and genetic covariates. RESULTS: 'Risk' alleles previously associated with smoking heaviness were significantly (P<0.05) associated with reduced abstinence in the PLA pharmacotherapy group (PG) at 6MO [for rs588765, odds ratio (95% confidence interval) 0.41 (0.17-0.99)], and at end of treatment and at 6MO [for rs1051730, 0.42 (0.19-0.93) and 0.31 (0.12-0.80)], and with increased abstinence in the NRT PG at 6MO [for rs588765, 2.07 (1.11-3.87) and for rs1051730, 2.54 (1.29-4.99)]. We observed significant heterogeneity in rs1051730 effects (F=2.48, P=0.021) between PGs. CONCLUSION: chr15q25.1 nAChR SNP risk alleles for smoking heaviness significantly increase relapse with PLA treatment and significantly increase abstinence with NRT. These SNP-PG associations require replication in independent samples for validation, and testing in larger sample sizes to evaluate whether similar effects occur in other PGs.
Authors: Li-Shiun Chen; Timothy B Baker; Megan E Piper; Naomi Breslau; Dale S Cannon; Kimberly F Doheny; Stephanie M Gogarten; Eric O Johnson; Nancy L Saccone; Jen C Wang; Robert B Weiss; Alison M Goate; Laura Jean Bierut Journal: Am J Psychiatry Date: 2012-07 Impact factor: 18.112
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Marissa A Ehringer; Hilary V Clegg; Allan C Collins; Robin P Corley; Thomas Crowley; John K Hewitt; Christian J Hopfer; Kenneth Krauter; Jeffrey Lessem; Soo Hyun Rhee; Isabel Schlaepfer; Andrew Smolen; Michael C Stallings; Susan E Young; Joanna S Zeiger Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2007-07-05 Impact factor: 3.568
Authors: F Patterson; R A Schnoll; E P Wileyto; A Pinto; L H Epstein; P G Shields; L W Hawk; R F Tyndale; N Benowitz; C Lerman Journal: Clin Pharmacol Ther Date: 2008-04-02 Impact factor: 6.875
Authors: Jane E Sarginson; Joel D Killen; Laura C Lazzeroni; Stephen P Fortmann; Heather S Ryan; Alan F Schatzberg; Greer M Murphy Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2011-01-25 Impact factor: 3.568
Authors: Shizhong Han; Bao-Zhu Yang; Henry R Kranzler; David Oslin; Raymond Anton; Joel Gelernter Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2011-03-28 Impact factor: 3.568
Authors: Pingxing Xie; Henry R Kranzler; Michael Krauthammer; Kelly P Cosgrove; David Oslin; Raymond F Anton; Lindsay A Farrer; Marina R Picciotto; John H Krystal; Hongyu Zhao; Joel Gelernter Journal: Biol Psychiatry Date: 2011-06-17 Impact factor: 13.382
Authors: Paul D Thomas; Huaiyu Mi; Gary E Swan; Caryn Lerman; Neal Benowitz; Rachel F Tyndale; Andrew W Bergen; David V Conti Journal: Pharmacogenet Genomics Date: 2009-07 Impact factor: 2.089
Authors: Li-Shiun Chen; Timothy B Baker; J Philip Miller; Michael Bray; Nina Smock; Jingling Chen; Faith Stoneking; Robert C Culverhouse; Nancy L Saccone; Christopher I Amos; Robert M Carney; Douglas E Jorenby; Laura J Bierut Journal: Clin Pharmacol Ther Date: 2020-08-04 Impact factor: 6.875
Authors: Li-Shiun Chen; Rayjean J Hung; Timothy Baker; Amy Horton; Rob Culverhouse; Nancy Saccone; Iona Cheng; Bo Deng; Younghun Han; Helen M Hansen; Janet Horsman; Claire Kim; Sharon Lutz; Albert Rosenberger; Katja K Aben; Angeline S Andrew; Naomi Breslau; Shen-Chih Chang; Aida Karina Dieffenbach; Hendrik Dienemann; Brittni Frederiksen; Jiali Han; Dorothy K Hatsukami; Eric O Johnson; Mala Pande; Margaret R Wrensch; John McLaughlin; Vidar Skaug; Henricus F van der Heijden; Jason Wampfler; Angela Wenzlaff; Penella Woll; Shanbeh Zienolddiny; Heike Bickeböller; Hermann Brenner; Eric J Duell; Aage Haugen; Joachim Heinrich; John E Hokanson; David J Hunter; Lambertus A Kiemeney; Philip Lazarus; Loic Le Marchand; Geoffrey Liu; Jose Mayordomo; Angela Risch; Ann G Schwartz; Dawn Teare; Xifeng Wu; John K Wiencke; Ping Yang; Zuo-Feng Zhang; Margaret R Spitz; Peter Kraft; Christopher I Amos; Laura J Bierut Journal: J Natl Cancer Inst Date: 2015-04-14 Impact factor: 13.506
Authors: Robert C Culverhouse; Li-Shiun Chen; Nancy L Saccone; Yinjiao Ma; Megan E Piper; Timothy B Baker; Laura J Bierut Journal: Nicotine Tob Res Date: 2020-02-06 Impact factor: 4.244
Authors: Naji C Salloum; Erica L F Buchalter; Swati Chanani; Gemma Espejo; Mahjabeen S Ismail; Randy O Laine; Maysaa Nageeb; A Benjamin Srivastava; Nicholas Trapp; Ludwig Trillo; Erica Vance; Michael Wenzinger; Sarah M Hartz; Sean P David; Li-Shiun Chen Journal: Pharmacogenomics Date: 2018-06-19 Impact factor: 2.533
Authors: Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Maggie Kozman; Jonathan Phuong; Meaghan Neary; Trinh Luu; Mark A Mandelkern Journal: Neuropsychopharmacology Date: 2013-02-21 Impact factor: 7.853
Authors: Henry R Kranzler; Rachel V Smith; Robert Schnoll; Afaf Moustafa; Emma Greenstreet-Akman Journal: Addiction Date: 2017-04-21 Impact factor: 6.526